治疗性HIV-1重组DNA疫苗的构建与免疫效果评价

目的　构建编码HIV- 1多表位抗原基因 (MEG)与p2 4基因嵌合的核酸疫苗 ,并评价其免疫效果。方法　将编码HIV -1多表位抗原基因 (MEG)与p2 4基因插入到真核表达载体pVAXI中 ,构建HIV- 1治疗性重组核酸疫苗质粒。通过ELISA试剂盒检测免疫恒河猴血清中HIV -1特异性抗体 ,并通过淋巴细胞转化实验检测HIV -1特异性T淋巴细胞增殖反应。结果　构建的重组核酸疫苗质粒pVAXI -MEGp2 4免疫恒河猴后 ,能有效地刺激产生T淋巴细胞特异性增殖反应 ,并诱导产生抗HIV -1特异性抗体。结论　所构建的重组核酸疫苗质粒能诱导机体产生免疫反应。

Construction and Vaccination of Recombinant HIV-1 DNA Vaccine for Therapeutic Use

Objective To construct the DNA vaccine contai ning HIV-1 multiple-epitope antigen gene and p24 gene and evaluate the immunologic al effect of the vaccine.Methods A recombinant DNA vaccine plas mid was constructed by inserting HIV-1 multiple-epitope antigen gene and p24 g en e into vector pVAXI.The HIV-1 specific antibodies in the sera of monkeys immuni zed with the vaccine were detected by ELISA.The HIV-1 specific T lymphocyte pro liferation was determined by lymphocyte transformation test. Results A recombinant vaccine plasmid pVAXI-MEGP24 was constructed .The expressed product stimulated the specific T lymphocyte proliferation effect ively and induced HIV-1 specific antibodies in monkeys. Conclusion The constructed DNA vaccine plasmid for therapeutic use indu ced strong immune response in monkeys.